[{"orgOrder":0,"company":"Arvinas","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"ARV-766","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arvinas \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Arvinas \/ Not Applicable"},{"orgOrder":0,"company":"Arvinas","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Luxdegalutamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arvinas","amount2":1.1599999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.1599999999999999,"dosageForm":"Tablet","sponsorNew":"Arvinas \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Arvinas \/ Novartis Pharmaceuticals Corporation"}]

Find Clinical Drug Pipeline Developments & Deals for Luxdegalutamide

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Novartis obtains worldwide development & commercialization rights to ARV-766, Arvinas’ 2nd-generation PROTAC androgen receptor degrader for prostate cancer, including its preclinical AR-V7 program.

                          Brand Name : ARV-766

                          Molecule Type : Small molecule

                          Upfront Cash : $150.0 million

                          April 11, 2024

                          Lead Product(s) : Luxdegalutamide,Abiraterone Acetate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Novartis Pharmaceuticals Corporation

                          Deal Size : $1,160.0 million

                          Deal Type : Licensing Agreement

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : ARV-766 is an investigational orally bioavailable PROTAC® protein degrader designed to degrade all clinically relevant resistance-driving point mutations of the androgen receptor (AR) and which being investigated forLate-line mCRPC.

                          Brand Name : ARV-766

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 08, 2023

                          Lead Product(s) : Luxdegalutamide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank